Abstract：Objective This study aimed to explore the clinical value of serum creatinine Cr / cystatin C CysC ratio as a predictor
of sarcopenia for patients with advanced non-small cell lung cancer NSCLC . Method This study included 134 advanced NSCLC
patients who were initially diagnosed and treated with chemotherapy in our hospital from January 2019 to January 2022. The skeletal
muscle index SMI at the third lumbar level measured by computed tomography CT and handgrip strength were used to diagnose
sarcopenia. The linear relationships between serum Cr/ CysC ratio and various nutritional parameters were determined by the Pearson's
correlation coefficient and the receiver operating characteristics ROC curve was used to evaluate its predictive value for
sarcopenia. Result 46 34. 3% of 134 advanced NSCLC patients were diagnosed with sarcopenia which was found in 35 males
33. 0% and 11 females 39. 3% . Serum Cr/ CysC ratio was positively correlated with with serum albumin value r = 0. 186 P =
0. 032 SMI r = 0. 288 P = 0. 020 and handgrip strength r = 0. 362 P < 0. 001 . The ROC curve showed that the best
threshold of serum Cr/ CysC ratio was 0. 872 and its AUC value was 0. 744 95%CI = 0. 660-0. 829 with a sensitivity of 84. 8% and
specificity of 61. 4% respectively. The serum Cr/ CysC ratio OR= 0. 005 95%CI = 0. 001-0. 061 P<0. 001 was identified as a
protect risk factor of sarcopenia for advanced NSCLC patients. Conclusion The serum Cr/ CysC ratio was significantly correlated with
skeletal muscle mass and muscle strength and it could be a simple and effective tool of sarcopenia screening for advanced NSCLC
patients.
沈丽丽,蔡锦洪,包亚红,李倩倩,刘剑辉. 血肌酐与胱氨酸抑素 C 比值对晚期非小细胞肺癌肌肉减少症的诊断价值[J]. 肿瘤代谢与营养电子杂志, 2023, 10(6): 806-811.
Shen Lili Cai Jinhong Bao Yahong Li Qianqian Liu Jianhui. The predictive value of serum serum creatinine / cystatin C ratio for sarcopenia in advanced non-small cell lung cancer. Electron J Metab Nutr Cancer, 2023, 10(6): 806-811.
